In Celexir’s portfolio, Thymosin Alpha-1 (Tα1) is positioned for immune optimization within aging and longevity care—used to reinforce host defense, reduce chronic inflammatory load, and support resilience in immunocompromised or older patients. Clinically it’s deployed as an adjunct across immune-focused protocols and cancer-immunotherapy support, reflecting its role in restoring coordinated T-cell activity and immune surveillance.
Mechanistically, Tα1 enhances T-cell function and antigen processing and supports immune surveillance; experimentally it activates dendritic cells and engages TLR/MyD88 signaling, boosting Th1-type cytokines and NK/CD8+ activity—pathways tied to vaccine responsiveness, antiviral defense, and tumor immunology. These effects map to longevity goals by improving immune competence and controlling inflammaging drivers.
Evidence spans decades and multiple indications. Reviews summarize Tα1 as an immunomodulator used internationally (e.g., chronic hepatitis, oncology adjuncts, vaccine adjuvant), though U.S. approval for longevity use does not exist. Recent large studies in sepsis and COVID-19 show mixed or null effects on mortality, underscoring that benefits are context-dependent and that modern, multicenter RCTs remain needed for aging endpoints. Frame use as investigational in longevity programs with informed consent and outcomes tracking.
Celexir delivery & specs: pre-dosed injectable pens (GMP, >98% purity) with 2–8 °C storage, full CoA/import documentation, and typical catalog protocols of 1.6–3 mg twice weekly adjusted to patient context. Position Tα1 alongside sleep, metabolic, and inflammation management; verify benefit with objective markers (infection frequency, vaccine response proxies, inflammatory panels) while monitoring tolerability.